0001415889-22-002081.txt : 20220301 0001415889-22-002081.hdr.sgml : 20220301 20220301200125 ACCESSION NUMBER: 0001415889-22-002081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220226 FILED AS OF DATE: 20220301 DATE AS OF CHANGE: 20220301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAMPROPOULOS FRED P CENTRAL INDEX KEY: 0000901534 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-18592 FILM NUMBER: 22700724 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MERIT MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0000856982 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870447695 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1600 WEST MERIT PARK WAY CITY: SOUTH JORDAN STATE: UT ZIP: 84095 BUSINESS PHONE: 8012531600 MAIL ADDRESS: STREET 1: 1600 WEST MERIT PARKWAY CITY: SOUTH JORDAN STATE: UT ZIP: 84095 4 1 form4-03012022_050303.xml X0306 4 2022-02-26 0000856982 MERIT MEDICAL SYSTEMS INC MMSI 0000901534 LAMPROPOULOS FRED P 1600 WEST MERIT PARKWAY SOUTH JORDAN UT 84095 true true false false PRESIDENT AND CEO Common Stock, No Par Value 2022-02-26 4 A 0 17680 0 A 985596 D Common Stock, No Par Value 2022-02-28 4 F 0 7832 65.03 D 977764 D Common Stock, No Par Value 96357 I By 401(k) Plan Common Stock, No Par Value 3859 I By spouse Common Stock, No Par Value 90 I By spouse as custodian for child Non-qualified stock options (right to buy) 65.03 2022-02-26 4 A 0 48566 0 A 2023-02-28 2029-02-28 Common Stock 48566 48566 D Non-qualified stock options (right to buy) 16.05 2017-01-28 2023-01-28 Common Stock 50000 50000 D Non-qualified stock options (right to buy) 16.05 2017-01-28 2023-01-28 Common Stock 6000 6000 I See footnote Non-qualified stock options (right to buy) 28.20 2018-04-14 2024-04-14 Common Stock 200000 200000 D Non-qualified stock options (right to buy) 28.20 2018-04-14 2024-04-14 Common Stock 6000 6000 I See footnote Non-qualified stock options (right to buy) 44.80 2019-03-02 2025-03-02 Common Stock 38002 38002 D Non-qualified stock options (right to buy) 44.80 2019-03-02 2025-03-02 Common Stock 4000 4000 I See footnote Non-qualified stock options (right to buy) 55.73 2020-03-01 2026-03-01 Common Stock 159151 159151 D Non-qualified stock options (right to buy) 55.73 2020-03-01 2026-03-01 Common Stock 2000 2000 I See footnote Non-qualified stock options (right to buy) 37.71 2021-02-26 2027-02-26 Common Stock 100334 100334 D Non-qualified stock options (right to buy) 56.25 2022-03-19 2028-03-19 Common Stock 58083 58083 D These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee and Board of Directors that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02/26/2020. Represents plan holdings as of 02/28/2022. Becomes exercisable in equal annual installments of 25% commencing 2/28/2023. Became exercisable in equal annual installments of 20% commencing 1/28/2017. Original grant of 7,500 options was to become vested and exercisable in equal annual installments of 20% commencing 1/28/2017. Options not vested as of 6/22/2020 have been forfeited. Becomes exercisable in equal annual installments of 20% commencing 4/14/2018. Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 4/14/2018. Options not vested as of 6/22/2020 have been forfeited. Becomes exercisable in equal annual installments of 20% commencing 3/2/2019. Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/2/2019. Options not vested as of 6/22/2020 have been forfeited. Becomes exercisable in equal annual installments of 20% commencing 3/1/2020. Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/1/2020. Options not vested as of 6/22/2020 have been forfeited. Becomes exercisable in equal annual installments of 25% commencing 2/26/2021. Becomes exercisable in equal annual installments of 25% commencing 3/19/2022. /s/ Brian G. Lloyd, Attorney-in-Fact 2022-03-01